Farther Finance Advisors LLC Purchases 1,125 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Farther Finance Advisors LLC grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 28.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,065 shares of the biotechnology company’s stock after buying an additional 1,125 shares during the quarter. Farther Finance Advisors LLC’s holdings in Exelixis were worth $169,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of EXEL. EverSource Wealth Advisors LLC increased its stake in shares of Exelixis by 40.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 947 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Exelixis by 16.1% during the 4th quarter. HighTower Advisors LLC now owns 75,119 shares of the biotechnology company’s stock worth $2,501,000 after purchasing an additional 10,391 shares during the last quarter. Wealthfront Advisers LLC purchased a new stake in shares of Exelixis during the 4th quarter worth approximately $2,728,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Exelixis by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,447 shares of the biotechnology company’s stock worth $2,113,000 after purchasing an additional 3,349 shares during the last quarter. Finally, Ruffer LLP purchased a new stake in shares of Exelixis during the 4th quarter worth approximately $3,688,000. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at $28,174,996.98. The trade was a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 over the last three months. Insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EXEL. Citigroup raised their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Stephens reiterated an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Royal Bank of Canada lifted their price objective on shares of Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Finally, Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Stock Performance

NASDAQ EXEL opened at $37.06 on Thursday. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The company has a market capitalization of $10.37 billion, a P/E ratio of 20.94, a P/E/G ratio of 1.13 and a beta of 0.57. The company has a fifty day moving average of $35.53 and a 200-day moving average of $32.71.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.